Article
The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.
Pharmacogenetics and genomics - 1 Apr 2013
Stage Tore B, Christensen Mette M H, Feddersen Søren, Beck-Nielsen Henning, Brøsen Kim
Abstract excerpt
OBJECTIVE: The aim of this study was to examine the effect of single nucleotide polymorphisms in CYP2C8, LPIN1, PPARGC1A and PPARγ on rosiglitazone's (i) trough steady-state plasma concentration (C(ss,min)), (ii) on glycosylated haemoglobin A1c (HbA1c) and (iii) the risk of developing adverse events, mainly oedema, in patients with type 2 diabetes mellitus (T2D). METHODS: The data used in this study were obtained...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.